share_log

Chison Medical Technologies' (SHSE:688358) Profits May Not Reveal Underlying Issues

Chison Medical Technologies' (SHSE:688358) Profits May Not Reveal Underlying Issues

Chison Medical Technologies(上海证券交易所代码:688358)的利润可能不会揭示潜在问题
Simply Wall St ·  04/25 18:39

Chison Medical Technologies Co., Ltd. (SHSE:688358) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weakening the foundations of those good profit numbers.

奇生医疗科技股份有限公司(SHSE: 688358)刚刚发布了一份稳健的收益报告,该股表现出一定的走强。尽管如此,我们的分析表明,有一些因素削弱了这些良好利润数字的基础。

earnings-and-revenue-history
SHSE:688358 Earnings and Revenue History April 25th 2024
SHSE: 688358 2024 年 4 月 25 日的收益和收入历史记录

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

Importantly, our data indicates that Chison Medical Technologies' profit received a boost of CN¥13m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. If Chison Medical Technologies doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我们的数据表明,奇生医疗科技的不寻常项目利润比去年增加了1300万元人民币。我们不能否认更高的利润通常会让我们感到乐观,但如果利润是可持续的,我们更愿意这样做。当我们计算数千家上市公司的数字时,我们发现,特定年份中不寻常的项目所带来的提振通常不会在第二年重演。而且,毕竟,这正是会计术语的含义。如果奇森医疗科技没有看到这种捐款重演,那么在其他条件相同的情况下,我们预计其本年度的利润将下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On Chison Medical Technologies' Profit Performance

我们对奇森医疗科技盈利表现的看法

We'd posit that Chison Medical Technologies' statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Chison Medical Technologies' statutory profits are better than its underlying earnings power. Nonetheless, it's still worth noting that its earnings per share have grown at 36% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Case in point: We've spotted 1 warning sign for Chison Medical Technologies you should be aware of.

我们认为,由于这个很大的不寻常项目,奇森医疗科技的法定收入并不能完全反映持续的生产力。因此,我们认为奇森医疗科技的法定利润可能好于其基础盈利能力。尽管如此,仍然值得注意的是,其每股收益在过去三年中增长了36%。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。考虑到这一点,除非我们对风险有透彻的了解,否则我们不会考虑投资股票。一个很好的例子:我们发现了奇森医疗科技的1个警告信号,你应该注意。

Today we've zoomed in on a single data point to better understand the nature of Chison Medical Technologies' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我们放大了单个数据点,以更好地了解奇生医疗科技利润的性质。但是,还有很多其他方法可以让你对公司的看法。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发